SPOTLIGHT: Sunesis cuts 60 jobs

Sunesis Pharmaceuticals is realigning to focus on the development voreloxin (SNS-595), its lead drug candidate. The company is expanding activities around late-stage development of the drug and reduced its workforce by 60 percent. The plan includes de-emphasizing research work. Sunesis said the move concentrates the company's assets "on the strongest path to potential near-term value creation for the company's stockholders." Release

Suggested Articles

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big change at the top.